Reporting from: – 2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida In this edition: Will they or won’t they relapse? For patients wit
Reporting from:
– 2005 Multidisciplinary Prostate Cancer Symposium, February 17-19, Hyatt Grand Cypress, Orlando, Florida
In this edition:
Will they or won’t they relapse? For patients with prostate cancer, their PSA velocity before radical prostatectomy best pinpoints the risk of relapse, according to Deep Patel.
Brachytherapy, rather than external beam radiation, may be the best option for patients with intermediate-risk prostate cancer, according to Vinai Gondi.
David Dearnaley has been using the latest precision radiotherapy tool, Intensity Modulated Radiotherapy – IMRT, successfully to treat affected nodes in locally advanced prostate cancer.
A new study reveals the possibility of extending life among patients with androgen independent prostate cancer. Eric Small discusses the final survival data from a phase-three trial of the vaccine APC 8015.
…
Tags
Related Episodes
Timothy Yap MD PhD MBBS: Selective PARP1 Inhibitor Saruparib Clinical Promise in Solid Tumors with Homologous Recombination Repair Deficiency
Timothy Yap MD PhD MBBS selective PARP inhibitor promise in breast, ovarian, pancreatic, prostate tumors.
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
Cora Sternberg REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007 CORA STERNBERG, San Camillo and Forlanini Hospital, Rome Satraplatin could pro
Audio Journal of Oncology in Advance – May 1st, 2007 – reporting from: American Association for Cancer Research 14-18 April, 2007 Los Angeles
Fritz Schröder Opportunistic Prostate Screening May Not Save Lives! REFERENCE: AACR 2007, Los Angeles FRITZ SCHRÖDER, Erasmus University, Rotterdam Though elective screening appears to have reduced